Immunogenicity 416

summary
Sample ID
None
Response
Negative
Tumor Type
Melanoma
Gene Symbol
DCAKD
Transcript ID
None
HLA INFO
B*44:02
TCR INFO

No TCR info found!

T cell Tumor cell B*44:02
sequence
Full length protein sequence (231 aa)
MFLVG
1
LTGGI
6
ASGKS
11
SVIQV
16
FQQLG
21
CAVID
26
VDVMA
31
RHVVQ
36
PGYPA
41
HRRIV
46
EVFGT
51
EVLLE
56
NGDIN
61
RKVLG
66
DLIFN
71
QPDRR
76
QLLNA
81
ITHPE
86
IRKEM
91
MKETF
96
KYFLR
101
GYRYV
106
ILDIP
111
LLFET
116
KKLLK
121
YMKHT
126
VVVYC
131
DRDTQ
136
LARLM
141
RRNSL
146
NRKDA
151
EARIN
156
AQLPL
161
TDKAR
166
MARHV
171
LDNSG
176
EWSVT
181
KRQVI
186
LLHTE
191
LERSL
196
EYLPL
201
RFGVL
206
TGLAA
211
IASLL
216
YLLTH
221
YLLPY
226
A
231
Mutation Information
DNA mutation:
None
Peptide Range:
194 ~ 216
Mut AA position:
199 (6 in Wild Type peptide)
Alignment
Wild Type:
"---------TELERSLEY-----
|||||.|||
Mutant:
TKRQVILLHTELERFLEYLPLRF"
reference

Nature, 2017

An immunogenic personal neoantigen vaccine for patients with melanoma

Gene Name (from Reference) DCAKD

clinic trial
Checkpoint Blockade

None

ACT

None

Vaccination

None

Curative Effect

None

experiment
minimal_peptide

None

Antigen Type

None

T-cell Source

PBMCs

APC Type

autologous APCs

Assay

IFNg ELISPOT assay